Broker’s Call: Manipal Health Enterprises Buy
Brokerage firm initiated coverage on Manipal Health Enterprises with a Buy rating, setting a target price of ₹1,000. The company, backed by Temasek Holdings, expects significant revenue and EBITDA growth driven by improved asset utilization and operational efficiency. The IPO proceeds will help reduce debt, enhancing financial stability ahead of FY27.